Edwards Lifesciences Current Ratio 2010-2022 | EW

Current and historical current ratio for Edwards Lifesciences (EW) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Edwards Lifesciences current ratio for the three months ending June 30, 2022 was 3.37.
Edwards Lifesciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $3.26B $0.97B 3.37
2022-03-31 $3.24B $0.95B 3.41
2021-12-31 $3.18B $1.03B 3.08
2021-09-30 $3.52B $0.97B 3.64
2021-06-30 $3.32B $0.89B 3.75
2021-03-31 $3.07B $0.80B 3.84
2020-12-31 $3.09B $0.89B 3.46
2020-09-30 $2.98B $0.85B 3.52
2020-06-30 $2.69B $0.87B 3.08
2020-03-31 $2.51B $0.75B 3.36
2019-12-31 $2.98B $0.90B 3.31
2019-09-30 $2.74B $0.78B 3.53
2019-06-30 $2.36B $0.70B 3.38
2019-03-31 $2.37B $0.65B 3.66
2018-12-31 $2.29B $0.88B 2.61
2018-09-30 $2.91B $1.26B 2.31
2018-06-30 $2.70B $1.45B 1.86
2018-03-31 $2.72B $1.32B 2.07
2017-12-31 $2.55B $1.42B 1.80
2017-09-30 $2.57B $0.74B 3.49
2017-06-30 $2.28B $0.56B 4.06
2017-03-31 $2.02B $0.59B 3.45
2016-12-31 $2.24B $0.53B 4.21
2016-09-30 $2.17B $0.53B 4.08
2016-06-30 $1.99B $0.48B 4.15
2016-03-31 $1.82B $0.46B 3.97
2015-12-31 $2.05B $0.48B 4.30
2015-09-30 $2.15B $0.53B 4.03
2015-06-30 $2.30B $0.45B 5.16
2015-03-31 $2.26B $0.41B 5.56
2014-12-31 $2.23B $0.43B 5.24
2014-09-30 $2.31B $0.43B 5.40
2014-06-30 $2.28B $0.54B 4.22
2014-03-31 $1.60B $0.36B 4.50
2013-12-31 $1.73B $0.35B 4.99
2013-09-30 $1.57B $0.34B 4.69
2013-06-30 $1.39B $0.31B 4.43
2013-03-31 $1.36B $0.30B 4.53
2012-12-31 $1.29B $0.35B 3.72
2012-09-30 $1.39B $0.30B 4.65
2012-06-30 $1.28B $0.28B 4.50
2012-03-31 $1.19B $0.27B 4.48
2011-12-31 $1.17B $0.34B 3.49
2011-09-30 $1.18B $0.30B 3.91
2011-06-30 $1.22B $0.31B 3.88
2011-03-31 $1.15B $0.45B 2.58
2010-12-31 $1.03B $0.34B 3.06
2010-09-30 $0.99B $0.38B 2.60
2010-06-30 $0.92B $0.25B 3.71
2010-03-31 $0.87B $0.24B 3.60
2009-12-31 $0.89B $0.29B 3.06
2009-09-30 $0.88B $0.30B 2.96
2009-06-30 $0.75B $0.25B 3.04
2009-03-31 $0.65B $0.20B 3.24
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $51.226B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $198.711B 20.24
Alcon (ALC) Switzerland $28.513B 24.14
STERIS (STE) Ireland $16.630B 20.66
Teleflex (TFX) United States $9.450B 15.06
Fresenius Medical Care AG KGaA (FMS) Germany $8.228B 7.59
Penumbra (PEN) United States $7.184B 861.82
Globus Medical (GMED) United States $5.928B 30.24
Glaukos (GKOS) United States $2.520B 0.00
Integer Holdings (ITGR) United States $2.061B 16.12
Nevro (NVRO) United States $1.649B 0.00
Paragon 28 (FNA) United States $1.368B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.031B 15.78
Artivion (AORT) United States $0.558B 53.23